111
Participants
Start Date
January 31, 2015
Primary Completion Date
March 29, 2022
Study Completion Date
March 29, 2022
Levofloxacin
Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido\[1,2,3-de\]-1,4benzoxazine-6-carboxylic acid hemihydrate.
Optimized background regimen (OBR)
"For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses."
Partners in Health, Lima
University of Cayetana Heredia, Lima
Stellenbosch University, Cape Town
Collaborators (1)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Centers for Disease Control and Prevention
FED
Macleods Pharmaceuticals Ltd
INDUSTRY
Boston University
OTHER